Navigation Links
Spectros T-Stat Tissue Oximeter Clinical Studies Presented at PAS (Pediatric Academic Societies') Conference
Date:5/19/2009

PORTOLA VALLEY, Calif., May 19 /PRNewswire/ -- Spectros announced today that its T-Stat Tissue Oximeter was featured in two presentations at the Pediatric Academic Societies' (PAS) annual conference held in Baltimore, Maryland, May 2-5, 2009. The studies focused on clinical applications of the Spectros T-Stat monitor in the neonatal intensive care unit (NICU).

The first abstract was titled, "Visible Light Spectroscopy (VLS) for Detecting Alterations in Tissue Oxygenation with PRBC Transfusion in Very Low Birth Weight (VLBW) Neonates." The authors noted, "VLS is an easy to use and noninvasive method of assessment of tissue saturation in VLBW neonates with various severity of illness."

The second poster was titled, "Noninvasive Measurements of Plasma Bilirubin Levels Using Real-Time Visible Light Spectroscopy." The authors concluded visible light spectroscopy can be used as a method to measure real-time plasma bilirubin levels noninvasively. This compliments prior studies showing T-Stat can measure tissue or plasma met-hemoglobin and carboxy-hemoglobin.

"The utilization and acceptance of T-Stat has grown tremendously over the past 16 months as clinicians have increasingly recognized the need to monitor tissue perfusion in a reliable, reproducible, and quantitative way," commented Michael Fierro, Director of Clinical Studies. "We have additional studies in progress and will continue to demonstrate the efficacy of the T-Stat in reducing hospitalization costs and improving outcome in this high-risk population."

About Spectros

Spectros markets advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's lead product, the T-Stat Tissue Oximeter, was the first medical device FDA-approved as sensitive to ischemia, an insufficient blood flow to tissue. T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art visible light spectroscopy (VLS) technology. In clinical use, T-Stat is a real-time, absolute, noninvasive, and continuous tissue monitor that analyzes 260 wavelengths of light, far more than the 2-4 wavelengths used in other monitors for superior accuracy.

Spectros is also developing molecular diagnostic tools for breast and prostate cancer currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.

(Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns. Certain Spectros applications described above have not been reviewed and approved by the FDA, and are for investigational use only. T-Stat is a registered trademark of the Spectros Corporation.)


'/>"/>
SOURCE Spectros
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Fluorescent glass SRMs are new tool for spectroscopy
2. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
3. Spectros Corporation Protects Its Cool White LED Spectroscopy Technology Against Alleged Infringement by Thermo Fisher Scientific
4. New Edition of Definitive Resource in Tissue Engineering Released Today
5. BioLife Solutions CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells
6. TEI Biosciences Launches SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction
7. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
8. US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue
9. The closest look ever at native human tissue
10. Starion Achieves Worldwide Distribution of Proprietary Tissue Welding Technology
11. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... ... Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on Wednesday, ... Stream, NY. The procedure was an anterior cervical discectomy and fusion on a ...
(Date:1/18/2017)... ... January 18, 2017 , ... Announced in ... Innovation Institutes (MII). U.S. Secretary of Commerce Penny Pritzker has announced the award ... Department of Defense has announced the award of a new Advanced Regenerative Manufacturing ...
(Date:1/18/2017)... New York, NY (PRWEB) , ... January 18, 2017 , ... Researchers from a ... antigen (PSA) do not fall low enough after prostate cancer treatment, this indicates there is ... a man’s risk of mortality. , “ The PSA test has always been an indicator ...
(Date:1/18/2017)... ... 2017 , ... BidMed, LLC, announced it will hold a 1-day ... equipment from two different leading institutes. This highly specialized laboratory equipment is coming directly ... This 1-day online auction will take place on BidMed’s website http://www.bidmed.com ...
Breaking Biology Technology:
(Date:1/11/2017)... Intoxalock, a leading ignition interlock provider, has ... patent-pending calibration device. With this new technology, Intoxalock is ... data logs and process repairs at service center locations, ... drunk driving through the application of cutting-edge technologies is ... also for the customer who can get back on ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., a ... scanning technology for automotive at CES® 2017. Delta ID ... ) to demonstrate the use of iris scanning as ... authenticate the driver in a car, and as a ... driving experience. Delta ID and Gentex will ...
Breaking Biology News(10 mins):